Loomis, Sayles & Company’s Encompass Health EHC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$10.7M Buy
106,093
+33,605
+46% +$3.48M 0.01% 378
2026
Q1
$7.01M Buy
+72,488
New +$7.43M 0.01% 392
2022
Q4
Sell
-21,505
Closed -$973K 893
2022
Q3
$973K Sell
21,505
-299,466
-93% -$15M ﹤0.01% 415
2022
Q2
$14.3M Buy
320,971
+37,360
+13% +$1.92M 0.03% 310
2022
Q1
$16M Buy
283,611
+69,965
+33% +$3.65M 0.02% 319
2021
Q4
$11.1M Sell
213,646
-96,325
-31% -$4.97M 0.01% 372
2021
Q3
$18.5M Buy
309,971
+8,818
+3% +$555K 0.02% 313
2021
Q2
$18.7M Buy
301,153
+11,834
+4% +$789K 0.02% 313
2021
Q1
$18.9M Buy
289,319
+44,840
+18% +$2.92M 0.02% 292
2020
Q4
$16.1M Buy
244,479
+29,056
+13% +$1.71M 0.02% 288
2020
Q3
$11.1M Sell
215,423
-2,258
-1% -$116K 0.02% 305
2020
Q2
$10.7M Buy
217,681
+16,783
+8% +$906K 0.02% 299
2020
Q1
$10.2M Buy
+200,898
New +$11.6M 0.02% 278
2019
Q2
Sell
-46,934
Closed -$2.18M 621
2019
Q1
$2.18M Buy
46,934
+46,460
+9,802% +$2.35M ﹤0.01% 502
2018
Q4
$23K Hold
474
﹤0.01% 659
2018
Q3
$29K Sell
474
-254
-35% -$15.4K ﹤0.01% 685
2018
Q2
$39K Sell
728
-175
-19% -$8.75K ﹤0.01% 636
2018
Q1
$41K Sell
903
-75
-8% -$3.21K ﹤0.01% 621
2017
Q4
$38K Buy
978
+206
+27% +$7.83K ﹤0.01% 640
2017
Q3
$28K Buy
772
+112
+17% +$3.99K ﹤0.01% 702
2017
Q2
$25K Sell
660
-271
-29% -$9.92K ﹤0.01% 727
2017
Q1
$32K Buy
931
+85
+10% +$2.79K ﹤0.01% 685
2016
Q4
$28K Sell
846
-504
-37% -$16.4K ﹤0.01% 727
2016
Q3
$44K Buy
1,350
+140
+12% +$4.54K ﹤0.01% 670
2016
Q2
$37K Buy
1,210
+5
+0.4% +$156 ﹤0.01% 665
2016
Q1
$36K Sell
1,205
-2,136
-64% -$59K ﹤0.01% 685
2015
Q4
$93K Hold
3,341
﹤0.01% 719
2015
Q3
$102K Buy
3,341
+2,941
+735% +$102K ﹤0.01% 742
2015
Q2
$15K Buy
+400
New +$14.3K ﹤0.01% 772

Other funds holding EHC

Loomis, Sayles & Company's EHC Position: Q2 2026 in Review

Loomis, Sayles & Company increased its Encompass Health (EHC) stake by 46% in Q2 2026, buying an estimated $3.48M and bringing the position to 106,093 shares worth $10.7M. The position accounts for 0.01% of the portfolio, ranked #378.

Loomis, Sayles & Company first reported a position in EHC in Q2 2015 and has held it in 29 quarters since. The position peaked at $18.9M in Q1 2021. 598 funds tracked by Wall St. Rank hold EHC as of Q2 2026.

  • Loomis, Sayles & Company held 106,093 shares of Encompass Health worth $10.7M as of Q2 2026.
  • Loomis, Sayles & Company bought 33,605 Encompass Health shares in Q2 2026, an estimated $3.48M.
  • Encompass Health made up 0.01% of Loomis, Sayles & Company's portfolio in Q2 2026, its #378 holding.
  • Loomis, Sayles & Company first reported a position in Encompass Health in Q2 2015 and has held it in 29 quarters since.
  • Loomis, Sayles & Company's Encompass Health position peaked at $18.9M in Q1 2021.
  • 598 funds tracked by Wall St. Rank held Encompass Health as of Q2 2026.

Based on Loomis, Sayles & Company's 13F filing for Q2 2026, filed 14 Aug 2026.